Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

DYRK1A and cognition: A lifelong relationship
María L. Arbonés, Aurore Thomazeau, Akiko Nakano-Kobayashi, et al.
Pharmacology & Therapeutics (2018) Vol. 194, pp. 199-221
Open Access | Times Cited: 150

Showing 1-25 of 150 citing articles:

Effects of air pollution on the nervous system and its possible role in neurodevelopmental and neurodegenerative disorders
Lucio G. Costa, Toby B. Cole, Khoi Dao, et al.
Pharmacology & Therapeutics (2020) Vol. 210, pp. 107523-107523
Open Access | Times Cited: 352
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview
Mattias F. Lindberg, Laurent Meijer
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 6047-6047
Open Access | Times Cited: 81
The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic Opportunities
Jacopo Boni, Carlota Rubio-Pérez, Núria López-Bigas, et al.
Cancers (2020) Vol. 12, Iss. 8, pp. 2106-2106
Open Access | Times Cited: 74
The Human Islet: Mini-Organ With Mega-Impact
John T. Walker, Diane C. Saunders, Marcela Briššová, et al.
Endocrine Reviews (2021) Vol. 42, Iss. 5, pp. 605-657
Open Access | Times Cited: 66
GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways
Stefania Demuro, Rita Maria Concetta Di Martino, José Antonio Ortega, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 9098-9098
Open Access | Times Cited: 60
Overproduction of hydrogen sulfide, generated by cystathionine β-synthase, disrupts brain wave patterns and contributes to neurobehavioral dysfunction in a rat model of down syndrome
Theodora Panagaki, Laura Lozano‐Montes, Lucia Janickova, et al.
Redox Biology (2022) Vol. 51, pp. 102233-102233
Open Access | Times Cited: 46
Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases
Mattias F. Lindberg, Emmanuel Deau, Jonas Arfwedson, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 4106-4130
Closed Access | Times Cited: 25
ncRNAs and their impact on dopaminergic neurons: Autophagy pathways in Parkinson's disease
Riya Thapa, Ehssan Moglad, Muhammad Afzal, et al.
Ageing Research Reviews (2024) Vol. 98, pp. 102327-102327
Closed Access | Times Cited: 13
Bioavailability of Epigallocatechin Gallate Administered with Different Nutritional Strategies in Healthy Volunteers
Vicente Andreu-Férnández, Laura Almeida-Toledano, Nieves Pizarro, et al.
Antioxidants (2020) Vol. 9, Iss. 5, pp. 440-440
Open Access | Times Cited: 62
Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells
Ariadna Recasens, Sean J. Humphrey, M. A. Ellis, et al.
Cell Death Discovery (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 45
The Omnipresence of DYRK1A in Human Diseases
Estelle Deboever, Alessandra Fistrovich, Christopher Hulme, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9355-9355
Open Access | Times Cited: 37
EGCG-like non-competitive inhibitor of DYRK1A rescues cognitive defect in a down syndrome model
Jean Maurice Delabar, Marco Antônio G. B. Gomes, Marta Fructuoso, et al.
European Journal of Medicinal Chemistry (2024) Vol. 265, pp. 116098-116098
Closed Access | Times Cited: 7
Shaping down syndrome brain cognitive and molecular changes due to aging using adult animals from the Ts66Yah murine model
Chiara Lanzillotta, Monika Rataj Baniowska, Francesca Prestia, et al.
Neurobiology of Disease (2024) Vol. 196, pp. 106523-106523
Open Access | Times Cited: 7
SR proteins in cancer: function, regulation, and small inhibitor
Mingrong Bei, Jianzhen Xu
Cellular & Molecular Biology Letters (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 6
APP and DYRK1A regulate axonal and synaptic vesicle protein networks and mediate Alzheimer’s pathology in trisomy 21 neurons
Chun-I Wu, Elizabeth A. Vinton, Richard V. Pearse, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 4, pp. 1970-1989
Open Access | Times Cited: 26
Intranasal Administration of KYCCSRK Peptide Rescues Brain Insulin Signaling Activation and Reduces Alzheimer’s Disease-like Neuropathology in a Mouse Model for Down Syndrome
Antonella Tramutola, Simona Lanzillotta, Giuseppe Aceto, et al.
Antioxidants (2023) Vol. 12, Iss. 1, pp. 111-111
Open Access | Times Cited: 15
Function and inhibition of DYRK1A: Emerging roles of treating multiple human diseases
Yuping Yang, Xiaoxiao Fan, Yongjian Liu, et al.
Biochemical Pharmacology (2023) Vol. 212, pp. 115521-115521
Closed Access | Times Cited: 14
Leucettinibs, a Class of DYRK/CLK Kinase Inhibitors Inspired by the Marine Sponge Natural Product Leucettamine B
Emmanuel Deau, Mattias F. Lindberg, Frédéric Miege, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10694-10714
Closed Access | Times Cited: 14
DYRK1A Up-Regulation Specifically Impairs a Presynaptic Form of Long-Term Potentiation
Aude-Marie Lepagnol-Bestel, Simon Haziza, Julia Viard, et al.
Life (2025) Vol. 15, Iss. 2, pp. 149-149
Open Access
Calcineurin inhibition may prevent Alzheimer disease in people with Down syndrome
Jacob Dohl, Zoe Treadwell, Christopher M. Norris, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 3
Open Access
DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition
V.S.S. Abhinav Ayyadevara, Gerald Wertheim, Shikha Gaur, et al.
Leukemia (2025)
Open Access
Risk of Alzheimer's disease in Down syndrome: Insights gained by multi‐omics
Hui‐Qi Qu, Yichuan Liu, John J. Connolly, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 4
Open Access
The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo
Luca Trovò, Claudia Fuchs, Roberta De Rosa, et al.
Neurobiology of Disease (2020) Vol. 138, pp. 104791-104791
Open Access | Times Cited: 32
Green tea extracts containing epigallocatechin-3-gallate modulate facial development in Down syndrome
John M. Starbuck, Sergi Llambrich, Rubèn Gonzàlez, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 29
State‐of‐the‐art therapy for Down syndrome
Nicola Lorenzón, Juanluis Musoles‐Lleó, Federica Turrisi, et al.
Developmental Medicine & Child Neurology (2023) Vol. 65, Iss. 7, pp. 870-884
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top